methylprednisolone hemisuccinate has been researched along with losartan potassium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brines, M; Carelli, S; Cerami, A; Coleman, T; De Biasi, S; Di Giulio, AM; Di Stefano, B; Gorio, A; Madaschi, L | 1 |
| Huang, Y; Wang, C; Xu, Y | 1 |
2 other study(ies) available for methylprednisolone hemisuccinate and losartan potassium
| Article | Year |
|---|---|
Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury.
Topics: Animals; Drug Interactions; Erythropoietin; Interleukin-6; Methylprednisolone Hemisuccinate; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Spinal Cord Injuries; Tumor Necrosis Factor-alpha | 2005 |
Effects of erythropoietin and methylprednisolone on AQP4 expression in astrocytes.
Topics: Animals; Animals, Newborn; Aquaporin 4; Astrocytes; Cell Hypoxia; Cell Survival; Erythropoietin; Female; Gene Expression Regulation; Glucose; Hypothalamus; Indoles; Methylprednisolone Hemisuccinate; Neuroprotective Agents; Oxygen; Primary Cell Culture; Protein Kinase C; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; RNA, Messenger; Signal Transduction | 2017 |